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A B S T R A C T
The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a treatment for women with
postpartum depression, and successful trials of a related neuroactive steroid, SGE-217, for men and women with
major depressive disorder offer the hope of a new era in treating mood and anxiety disorders based on the
potential of neurosteroids as modulators of brain function. This review considers potential mechanisms con-
tributing to antidepressant and anxiolytic effects of allopregnanolone and other GABAergic neurosteroids fo-
cusing on their actions as positive allosteric modulators of GABAA receptors. We also consider their roles as
endogenous “stress” modulators and possible additional mechanisms contributing to their therapeutic effects.
We argue that further understanding of the molecular, cellular, network and psychiatric effects of neurosteroids
offers the hope of further advances in the treatment of mood and anxiety disorders.
1. Introduction
Psychiatric illnesses are major causes of disability and death. In the
United States (US), mental illnesses account for at least one-third of all
disabilities across the human life-span (Friedrich, 2017; Mokdad et al.,
2004; Murray, 2013). Patients with severe psychiatric disorders also die
considerably earlier than expected with causes of death including me-
tabolic and cardiovascular illnesses, violence and suicide; in the US, the
suicide rate has risen over the past 20 years and now claims more than
40,000 lives per year. Major depression and anxiety disorders are
among the most common psychiatric illnesses and are leading con-
tributors to disability and suicide (Friedrich, 2017). Current treatments,
including medications, neuromodulation methods and evidence-based
forms of psychotherapy, can be effective but, under the best of cir-
cumstances, up to one-third of patients fail to respond to treatment.
Even among those who respond, relapses are common (Conway et al.,
2017). Additionally, since the advent of the selective serotonin re-
uptake inhibitors (SSRIs) more than 30 years ago, pharmacological
treatments have changed very little. Thus, there is substantial need to
better understand the biology of depression and anxiety and to develop
treatments with novel mechanisms of action. The recent FDA approvals
of esketamine for treatment resistant major depression and brexanolone
for postpartum depression offer new hope. Brexanolone is a cyclodex-
trin-based formulation of the neurosteroid, allopregnanolone (AlloP),
suitable for intravenous infusion (Kanes et al., 2017; Meltzer-Brody
et al., 2018). AlloP is a potent and effective positive allosteric mod-
ulator (PAM) of GABA-A receptors (GABAARs) and we will discuss its
effects on these receptors as well as other possible mechanisms con-
tributing to its antidepressant and anxiolytic effects (Majewska et al.,
1986; Belelli and Lambert, 2005; Esser et al., 2006; Zorumski et al.,
2013).
2. Neurosteroids, neuroactive steroids & GABAARs
The term “neurosteroid” was coined by Baulieu in the early 1980's
to describe endogenous steroids that are synthesized in the central
nervous system from cholesterol or sterol precursors (Baulieu, 1997).
AlloP is the prototype for these neurosteroids, but is only one of mul-
tiple neurosteroids that have been identified. Subsequent work showed
that both endogenous and exogenous steroids can modulate nervous
system function and, to account for this broader array of molecules,
Paul and Purdy (1992) proposed the term “neuroactive steroid” (NAS).
In this review, we will use the terms neurosteroid and NAS inter-
changeably but will point out specific instances where we are
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describing the effects of endogenously produced neurosteroids.
Although most endogenous neurosteroids have minimal or no ac-
tions at classical nuclear hormone receptors (Rupprecht et al., 1993;
Rupprecht and Holsboer, 1999), it is clear that these steroids can alter
the function of multiple receptors, ion channels and intracellular tar-
gets. Thus it is unlikely that any of the endogenous steroids are com-
pletely selective for one specific target. However, synthetic NAS can be
made to be highly selective for a given target. The recent successful
clinical trials with brexanolone and an orally-active synthetic NAS,
SGE-217 (zuranolone), both of which have potent GABAAR activity, for
postpartum depression and major depression highlight the likely im-
portance of GABAARs as a target for understanding the psychotropic
effects of these agents. Hence we will focus heavily on their GABAergic
actions in this review (Gunduz-Bruce et al., 2019; Kanes et al., 2017;
Martinez Botella et al., 2017; Meltzer-Brody et al., 2018).
To describe the effects of neurosteroids on GABAARs, it is important
to understand the complexities of these receptors, especially since not
all superficially similar GABAAR modulators have antidepressant ac-
tion. GABAARs are pentameric chloride channels that are activated
(gated) by the neurotransmitter, GABA. To date, 19 GABAAR subunits
have been identified (α1-6, β1-3, γ1-3, δ, ε, ρ1-3, π, Ɵ) and most native
GABAARs express three subunits (usually with 2α, 2β and a third sub-
unit, although receptors with only one or two subunit types have been
described) (Chuang and Reddy, 2018; Johnston, 2005; Korpi and
Sinkkonen, 2006; Olsen and Sieghart, 2009). Importantly, different
types of GABAARs mediate different forms of inhibition in the brain.
Phasic (synaptic) inhibition usually involves GABAARs that express γ2
subunits, while more persistent, tonic inhibition is mediated by extra-
synaptic receptors that often, although not always, contain a δ-subunit
(Belelli et al., 2009; Brickley and Mody, 2012; Farrant and Nusser,
2005; Glykys et al., 2008; Prenosil et al., 2006). Receptors mediating
tonic inhibition typically differ from those mediating phasic inhibition
in their higher sensitivity to GABA, slower ion channel kinetics and
weaker desensitization. NAS appear to affect GABAARs promiscuously,
with little selectivity for various subtypes, although, as will be dis-
cussed later, some evidence suggests preferential effects on δ-subunit
expressing extrasynaptic receptors (Belelli and Lambert, 2005; Stell
et al., 2003; Wohlfarth et al., 2002).
Broadly speaking, NAS have one of three effects on GABAARs.
Certain NAS are GABAAR PAMs, enhancing the actions of GABA at the
broad range of these receptors expressed in brain. AlloP (3α-hydroxy-
5α-pregnan-20-one) is the prototype for these GABAergic PAMs, but
PAM activity is shared by other 5α-reduced (planar) neurosteroids (e.g.
3α-hydroxy-5α-tetrahydro-deoxycorticosterone,THDOC) and by certain
5β-reduced (bent) NAS (e.g. SGE-217, a NAS in late stage human trials
for major depression, and the endogenous neurosteroid, pregnanolone)
(Majewska et al., 1986; Belelli and Lambert, 2005; Martinez Botella
et al., 2017). Structurally, GABA PAMs typically have a hydrogen bond
donor in the 3α-position of the steroid A-ring (a hydroxyl group in
AlloP) and a hydrogen bond acceptor in the 17β-position of the steroid
D-ring (a methylketone for AlloP). The PAMs have similar actions in
that they enhance the effects of sub-saturating concentrations of GABA
at sub-micromolar NAS concentrations (Puia et al., 1990). At somewhat
higher concentrations, PAMs can directly open GABAARs in the absence
of GABA (referred to as direct channel gating) via a site independent of
the GABA binding site (Alvarez et al. (2019). A primary effect of these
modulators appears to make GABA and other agonists more efficacious;
in addition to shifting the EC50 for orthosteric agonists to lower con-
centrations, the maximum effect of partial agonists is enhanced
(Wohlfarth et al., 2002) (Fig. 1).
A second class of NAS act as negative allosteric modulators (NAMs)
at GABAARs, and are activation-dependent, non-competitive inhibitors.
Examples of NAMs include steroids that are sulfated at the 3-position of
the steroid A-ring (as opposed to having a hydroxyl group in the 3α-
position in NAS PAMs). Examples include pregnenolone sulfate
(PREGS) and dehydroepiandrosterone sulfate (DHEAS) (Eisenman
et al., 2003; Seljeset et al., 2018; Shen et al., 2000). Steroids that have a
hydroxyl group in the 3-beta position are also GABAAR NAMS at suf-
ficiently high concentrations (Wang et al., 2002). Interestingly, these
NAMs can inhibit the effects of NAS PAMs and have sometimes been
considered to be antagonists of NAS PAMs, although they are not se-
lective for NAS PAMs (Wang et al., 2002). Most sulfated NAS also al-
losterically modulate NMDA-type glutamate receptors. Some have PAM
activity, and others have NAM activity at these receptors. The NMDA
receptor actions are of clinical neuropsychiatric interest, and several
groups, including ours, are interested in the medicinal chemistry of
sulfated NAS around NMDA receptors. The physiological (as opposed to
pharmacological) significance of the sulfated neurosteroids remains
unclear given discrepancies in their reported brain levels (Gibbs et al.,
2006).
Other NAS have little or no intrinsic activity at GABAARs, yet some
of these steroids can inhibit the action of NAS PAMs. Somewhat sur-
prisingly, the ability of certain neutral allosteric ligands (NALs) to in-
hibit NAS PAMs shows selectivity for 5α-over 5β-reduced NAS PAMs.
The reasons for this apparent selectivity remain uncertain. An example
of a NAL is (3α,5α)-17-phenylandrost-16-en-3-ol (17-PA) (Mennerick
et al., 2004). Fig. 2 shows structures of several of the steroids discussed
in this section and elsewhere in this paper.
3. Effects of neurosteroids on GABAARs
The remainder of this review will focus on effects of natural and
synthetic NAS PAMs, including actions on GABAARs and possible ad-
ditional mechanisms that may contribute to antidepressant effects. In
this section, we highlight five main points about NAS PAMs that em-
phasize important aspects of their actions and contribute to con-
siderations for future drug development.
3.1. Point #1. Neurosteroids are potent, effective and broad spectrum
GABAAR PAMs
AlloP and its structural analogues enhance the efficacy of GABA at
GABAARs and have threshold effects at nanomolar concentrations
(Majewska et al., 1986; Puia et al., 1990; Belelli and Lambert, 2005).
Thus, these steroids are among the most potent GABAAR PAMs identi-
fied to date, rivaling benzodiazepines. In addition to high potency, the
PAMs are highly effective modulators enhancing responses to low
concentrations of GABA by 10-fold or greater, similar to barbiturates
(Fig. 1). At the single channel level, NAS exert three major actions to
enhance receptor function. These actions include increasing the dura-
tion of long channel open times, decreasing activation-dependent
Fig. 1. Typical pharmacological effects of NAS PAMs on GABAA receptor
function at the whole-cell level. NAS at a modest, fixed concentration usually
shift the GABA EC50 value to the left and increase the maximum GABA re-
sponse, i.e., increase agonist efficacy. Because GABA is a lower efficacy agonist
on δ-containing receptors than on γ2-containing receptors, NAS may have a
somewhat larger effect on δ containing receptors.
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closed times within clusters of channel openings and increasing the
frequency of long channel openings (Akk et al., 2004). Some NAS ex-
hibit all of these effects while others have only one or two effects; de-
creases in intra-cluster closed times appear to be particularly important
for the prolongation of decay of GABA-mediated synaptic currents
(Chakrabarti et al., 2016).
NAS PAMs are also broad-spectrum enhancers of GABAARs, po-
tentiating responses at both synaptic (phasic) and extrasynaptic (tonic)
receptors (Herd et al., 2007). Some evidence suggests that the PAMs
may have preferential effects on GABAARs that express δ-subunits and
thus have major effects on tonic inhibition (Stell et al., 2003). It is clear
that NAS PAMs augment tonic inhibition but whether this reflects se-
lective effects on δ-expressing receptors is uncertain. An alternative
hypothesis is that δ-expressing receptors are low efficacy channels with
GABA serving as a partial agonist; the large enhancement of these tonic
currents may reflect the increase in efficacy of GABA as a partial agonist
at δ-containing receptors, a mechanism that may be shared by other
PAMs (Feng and Forman, 2018; Shu et al., 2012). Recent studies have
convincingly demonstrated that GABAARs with δ-subunits are activated
by synaptically released GABA and contribute to phasic inhibition (Sun
et al., 2018); thus, effects on δ-receptors may not be selective for tonic
inhibition. Despite these caveats, it is clear that NAS augment both
tonic and phasic inhibition in contrast to benzodiazepines, which pri-
marily augment phasic inhibition. Attempts are underway to identify
NAS that may have more selectivity for δ-expressing or other subtypes
of GABAARs (Shu et al., 2012). Also, given that other GABAAR PAMs
(e.g. benzodiazepines) do not appear to exhibit antidepressant benefit,
a bias toward δ-containing receptors (and augmenting tonic inhibition)
is an attractive explanation for the unique psychoactive profile of NAS.
It is also important to consider other subtypes of GABAARs and how
they might contribute to antidepressant and anxiolytic actions. Recent
studies suggest that actions at GABAARs expressing α2 subunits
involved in both tonic and phasic inhibition contribute to anxiolytic-
like effects of NAS but not to antidepressant effects (Durkin et al.,
2018). This finding echoes work showing that the anxiolytic effect of
benzodiazepines primarily involves α2 -containing GABAARs (Low
et al., 2000) and raises the possibility that agents with selective effects
on mood or anxiety can be developed.
3.2. Point #2. High potency does not mean high affinity for GABAARs
NAS are highly lipophilic molecules with log P's (octanol/water
partition coefficients) typically ranging from about 2 to 5 (Chisari et al.,
2009, 2010). This means that NAS accumulate preferentially in hy-
drophobic regions of cells including plasma membranes. Thus, for a
steroid such as AlloP (with a logP above 4), accumulation in hydro-
phobic regions can lead to concentrations that are 10,000-fold higher
than in aqueous environments. Studies examining NAS with logPs that
differ over the range of 2 to> 4 demonstrated that potency for po-
tentiating GABAARs correlates well with logP, with the highest potency
(lowest EC50) being observed with the most lipophilic of the steroids
(in the case of this study, AlloP > THDOC > alphaxalone >
alphadolone (Chisari et al., 2009, 2010).
Given the high lipophilicity of NAS, it is important to consider
whether high aqueous potency reflects high receptor affinity.
Unfortunately, there are no acceptable binding assays for these steroids
to test this possibility. As an alternative, Shu et al. (2004) took ad-
vantage of the fact that cyclodextrins can be used as “molecular
sponges” to extract NAS from membranes and cells. Using a NAS PAM
with a fluorescent NBD group at the C-11 steroid position, these studies
showed that the prolonged decay of currents directly gated by the
steroid was unlikely to result from high affinity drug-receptor interac-
tions but rather reflected the high intramembranous concentration of
the NAS. Similarly, the slow decay of intracellular fluorescence
Fig. 2. The figure shows structures of AlloP and several other NAS discussed in the text.
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produced by NAS accumulation was also greatly speeded by cyclodex-
trin and the decay of GABAAR currents and cellular fluorescence were
closely correlated. Similar results were obtained examining potentia-
tion of GABA-gated currents by NAS (Chisari et al., 2010; Shu et al.,
2007). These and related studies also provided evidence that NAS ac-
cess their site(s) of action on GABAARs via the plasma membrane (Akk
et al., 2005, 2007) and that the ability of NAS to accumulate in-
tracellularly can lead to situations where intracellular pools are either a
sink or a source for steroid acting at intramembranous sites on receptors
(Jiang et al., 2016; Li et al., 2007).
3.3. Point #3. GABAAR pharmacophore considerations are important
While NAS hydrophobicity is important for optimizing the potency
and likely efficacy of NAS on GABAARs, it is also important to consider
how NAS interact with their sites of action on receptors. The most direct
support for this issue comes from studies using NAS enantiomers.
Dating to studies in the late 1990's, it has been known that the effects of
NAS PAMs on GABAARs are enantioselective, with selectivity being
greater for 5α-reduced NAS compared to 5β-reduced steroids (Covey
et al., 2000, 2001; Wittmer et al., 1996) (Fig. 2). Studies of en-
antiomeric steroids are important because enantiomers (unlike stereo-
isomers) have identical physico-chemical properties, including logP,
and differ only in their rotation of polarized light (Alakoskela et al.,
2007). Studies of NAS enantiomers provided the first strong evidence
that NAS interact with chiral (likely protein) sites rather than exerting
effects by changes in membrane properties, even though 5α-reduced
steroids increase the liquid disordered state of membranes resulting in
higher lateral membrane mobility (Balleza et al., 2015; Sacchi et al.,
2015). Using fluorescent enantiomeric steroids, Chisari et al. (2009)
found that only NAS with the natural configuration of natural neuro-
steroids were able to potentiate GABA currents while both enantiomers
accumulated identically in cell membranes and intracellular compart-
ments.
Detailed structure-activity studies have determined the basis for the
enantioselectivity of NAS, with the size and position of the functional
group on the D-ring being a critical determinant (Katona et al., 2008).
This structural information made possible the preparation of en-
antiomeric steroid PAMs with high activity at GABAARs (Krishnan
et al., 2012; Qian et al., 2014). It is unlikely that these active en-
antiomeric steroids are metabolized in the same way as endogeneous
NAS and this could lead to enantiomeric NAS with longer in vivo half-
lives and less interference with endogenous steroid biotransformations.
A longer duration of anticonvulsant activity has been found with the
active enantiomers of androsterone and etiocholanolone (Zolkowska
et al., 2014).
Enantiomers may be attractive tool compounds to explore the im-
portance of GABAARs in the psychoactive effects of NAS. Some of the
biological effects of NAS-like compounds do not show strong en-
antioselectivity, including some anti-inflammatory and neuroprotective
effects of NAS PAMs (Langmade et al., 2006), and the NAM effects on
GABAARs of sulfated NAS (Nilsson et al., 1998). If GABA inactive en-
antiomers retain effects on circuits and behaviors indicative of anti-
depressant actions, the role of GABAARs in clinical benefit would be
seriously questioned.
3.4. Point #4. NAS interact with multiple sites in hydrophobic regions of
GABAARs
While studies using enantiomers provided support for the idea that
NAS act directly on GABAARs, more definitive evidence for direct in-
teractions came from studies of Hosie et al. (2006; 2008) using site-
directed receptor mutagenesis. These investigators found that NAS in-
teract with multiple amino acid residues in α1 subunits located in
transmembrane (TM) spanning regions 1 and 4. In TM1 key loci in-
cluded glutamine-241 (Q241) and tryptophan-245 (W245), while key
sites in TM4 included asparagine-407 (N407) and tyrosine-410 (Y410).
These sites contribute to the ability of NAS to enhance the function of
GABAARs. This work also raised the possibility that direct gating of
GABA channels by NAS may involve a separate site involving threonine-
236 (T236) in α1 subunits and tyrosine-284 (Y284) in β2 subunits.
Subsequent studies using NAS photoaffinity labels in β3 homo-
pentamers and in α1β3 pentamers identified phenylalanine-301 (F301)
in TM3 as a target for NAS interactions (Chen et al., 2012b, 2019).
Advances in structural biology provided further insights and clar-
ifications into how NAS PAMs interact with GABAARs. Based on elegant
cryo-electron microscopic and x-ray crystallographic structures of chi-
meric GABAARs, it appears that NAS promote potentiation and gating
via a single interfacial site that involves TM1, TM3 and TM4. In this
model, the steroid 3α-hydroxyl group appears to interact with Q241 in
TM1 along with W245, consistent with hydrophobic stacking of steroid
rings. The hydrogen bond acceptor on the steroid D-ring interacts with
TM3 at a site analogous to F301 (Laverty et al., 2017). Other structural
evidence indicates that the NAS binding site is coupled to helices that
form the channel pore and modulate the receptor conformation un-
derlying receptor desensitization (Miller et al., 2017).
Recent studies using novel NAS photoaffinity labels and click
chemistry that allow bio-orthogonal protein labeling provide evidence
of even further complexity in how NAS interact with GABAARs (e.g. KK-
123, Fig. 2). Using α1β3 pentamers, these studies indicate that NAS
interact with at least 7 sites in 3 clusters, representing both intersubunit
and intrasubunit interactions (Chen et al., 2019). This study provides
support for intrasubunit interactions between TM4 and TM1 of α1
subunits including homologous sites for N407 and Y410 outlined above,
as well as intersubunit interactions between Q241 in TM1 of α1 and
F301 in the TM3 region of β3. In addition, intrasubunit sites within the
TM3 and TM4 regions of β3 were also identified; these latter novel
residues are located toward the extracellular portion of β3. Based on
mutagenesis experiments, it appears that all of these sites contribute to
the effects of NAS on GABAARs with the α1 intrasubunit and β3-α1
intrasubunit sites being most critical for NAS activity; furthermore, it
does not appear that there are separate sites for receptor potentiation
and direct gating. At present, the roles of the intrasubunit sites on β3
are the least understood. See Alvarez et al. (2019) for an overview of
sites contributing to NAS effects.
3.5. Point #5. NAS accumulate intracellularly and interact with Golgi and
specific intracellular proteins
Studies using fluorescent NAS and photoaffinity labels highlight the
fact that these molecules also readily accumulate in intracellular com-
partments. In particular, studies using a clickable photoaffinity label
(e.g. KK-123, Fig. 2) indicate preferential labeling of Golgi, although
specific protein targets have not yet been identified. Interestingly, in-
tracellular accumulation and Golgi labeling are not enantioselective,
and prior studies have indicated that certain actions of NAS including
effects on inflammatory responses and perhaps neuronal survival, un-
like GABAAR effects, are also not enantioselective (Jiang et al., 2016;
Langmade et al., 2006). Furthermore, a similar pattern of cellular ac-
cumulation in Golgi is evident regardless of whether the cells are alive
or dead at the time of labeling. Thus, the role of active transport me-
chanism in the profile of accumulation remains unclear.
Photoaffinity labeling studies have begun to identify several po-
tential intracellular NAS targets. These include labeling of voltage-de-
pendent anion channel-1 (VDAC-1), a key mitochondrial protein in-
volved in regulating the mitochondrial permeability transition pore
(mPTP), at glutamate-73 (Darbondi-Tonkabon et al., 2003); this parti-
cular residue also interacts with cholesterol (Budelier et al., 2017). NAS
PALs also label β-tubulin, a microtubule protein, at cysteine-354. This
latter site is the locus that binds colchicine (Chen et al., 2012a). The
function of these intracellular sites for NAS remains uncertain.
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4. How do NAS act as antidepressants and anxiolytics?
It is safe to say that we presently don't understand exactly how AlloP
and other NAS PAMs act as antidepressants. Our discussion to this point
has emphasized prominent GABAAR effects that are likely to contribute
to psychotropic actions. However, other GABA enhancing drugs (e.g.
benzodiazepines) do not appear to be effective antidepressants, so NAS
seem to be unique among GABAAR PAMs. This suggests that NAS may
have additional (or alternative) targets that are important for anti-
depressant effects. However, as highlighted above, NAS, in contrast to
benzodiazepines, augment GABA via multiple GABAARs. Some evi-
dence also suggests that changes in endogenous NAS levels could par-
ticipate in the etiology of some depressive illnesses. In this section we
will discuss aspects of endogenous neurosteroid actions within brain as
a framework for understanding recent clinical findings.
4.1. Lessons from rodent models
Neurosteroids including AlloP are synthesized endogenously in
brain. Several cell types including astrocytes and neurons exhibit neu-
rosteroid synthesis in response to various stimuli (Rupprecht and
Holsboer, 1999). Importantly, in the presence of stressors, neurons
acutely increase production of 5α-reduced neurosteroids, and this
neurosteroidogensis is observed primarily within excitatory neurons
(Agis-Balboa et al., 2006; Saalman et al., 2007; Tokuda et al., 2010,
2011) (Fig. 3A). Both behavioral and metabolic/cellular stressors
greatly enhance neurosteroid production. This effect was shown in-
itially and dramatically by Purdy et al. (1991) using a forced swim
behavioral task. AlloP levels in brain increased within minutes of the
stress and remained elevated for over 2 h, exceeding levels that were
observed in the periphery. Other behavioral stresses including foot
shock have yielded similar results (Barbaccia et al., 1997). Studies over
the past decade have shown that cellular and metabolic stressors also
acutely enhance local production of AlloP in CA1 hippocampal pyr-
amidal neurons. These stressors include exposure to high ethanol con-
centrations (Izumi et al., 2007; Tokuda et al., 2011), acetaldehyde
(Tokuda et al., 2013), ammonia (Izumi et al., 2013) and corticosterone
(Izumi et al., 2015). Similarly, there is evidence that high pressure
stress results in acute AlloP production in retinal ganglion cells where it
plays a neuroprotective role (Ishikawa et al., 2014). Interestingly, the
various activating stressors result in stimulation of N-methyl-D-aspar-
tate glutamate receptors (NMDARs), and in cases where this has been
studied, the increases in neurosteroids can be blocked by NMDAR an-
tagonists administered during the period of stressor exposure (Guarneri
et al., 1998; Ishikawa et al., 2014; Kimoto et al., 2001; Tokuda et al.,
2011; Zorumski et al., 2013). Also low concentrations of NMDA itself
(1–10 μM) can promote neurosteroid synthesis in CA1 pyramidal neu-
rons (Tokuda et al., 2011). Taken together, these studies strongly sug-
gest that AlloP-type neurosteroids can be viewed as acute, “on-demand”
stress modulators (Gunn et al., 2011). How cellular stress activates
AlloP synthesis is not entirely clear, although there is evidence that
under toxic conditions activation of stress responses in endoplasmic
reticulum (ER) promotes movement of cholesterol from ER to mi-
tochondria where cholesterol undergoes side chain cleavage to preg-
nenolone, the first and critical step leading to neurosteroid (AlloP)
synthesis (Barbero-Camps et al., 2014).
From the perspective of major depression and other psychiatric
illnesses it is important to consider what happens with more prolonged
stress. This issue has been studied in most detail in models of chronic
behavioral stress (Locci and Pinna, 2017; Pinna, 2019). Although levels
of AlloP increase acutely with behavioral stress, over several weeks of
ongoing social isolation, rodents exhibit a variety of stress-like beha-
viors including changes in response to contextual fear tasks and the
ability to extinguish fear responses (Evans et al., 2012; Pinna et al.,
2003; Pibiri et al., 2008). These changes correlate with decreases in the
levels of AlloP and its precursor 5α-dihydroprogesterone (DHP) with no
changes observed in levels of pregnenolone or progesterone (Dong
et al., 2001). Changes in neurosteroid levels are accompanied by de-
creases in brain transcription and protein expression of 5α-reductase
(5AR), a key enzyme in neurosteroid synthesis. Another enzyme in
steroid synthesis, 3α-hydroxysteroid reductase, shows no change (Dong
et al., 2001; Agis-Balboa et al., 2007). Treatment with agents that in-
hibit 5AR mimic the effects of chronic stress on AlloP levels and be-
havior, and treatments that enhance AlloP levels in chronically stressed
animals can reverse behavioral changes (Pibiri et al., 2008). Based on
these results, it appears that, unlike acute stress, chronic stress results in
a state of relative AlloP deficiency and/or synthetic capability that
contributes to changes in depressive- and anxiety-like behaviors
(Fig. 3A). Thus, NAS may be more appropriately conceptualized as
modulators of brain stress states than as strict antidepressants.
4.2. Are changes in neurosteroid levels in rodent stress models relevant to
human major depression?
Evidence gathered over the past 20 years examining changes in
neurosteroids in major depression are suggestive, but not definitive.
Multiple studies have documented decreases in the levels of AlloP in
cerebrospinal fluid (CSF) and blood in patients with major depression
(Girdler and Klatzkin, 2007; Romeo et al., 1998; Schule et al., 2011;
Strohle et al., 1999; Uzunova et al., 1998). In some of these studies, the
Fig. 3. Possible endogenous and exogenous NAS roles in depression-like syndromes. A, B. Endogenous NAS levels change as a result of stress and postpartum
hormonal changes. In stress (panel A), acute stressors increase NAS levels, but more chronic stress may lead to a state of NAS deficiency, contributing to symptoms. B.
In pregnancy, NAS levels rise, and GABA receptor expression decreases, yielding stable inhibition. Following the sudden loss of NAS at parturition (dotted red line),
recovery of GABA receptor expression lags, creating a hyperexcitable state that may persist and participate in symptomology of postpartum depression. C, D. Two
intracellular pathways through which NAS may have underappreciated beneficial effects: by activating autophagy (panel C) and by inhibiting neuroinflammation
(panel D). See text for details and citations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this
article.)
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levels of the neurosteroids increase following successful treatment of
depression and these increases correlate with clinical improvement
(Uzunova et al., 1998). There is also tentative evidence for changes in
the expression of key enzymes in neurosteroid synthetic pathways.
Consistent with a decrease in levels of AlloP in depression, Agis-Balboa
et al. (2014) observed about 50% decrease in the expression of 5AR-
type I in pyramidal neurons of prefrontal cortex in a small sample of
postmortem brains from patients with major depression. Interestingly,
patients with post-traumatic stress disorder (PTSD), a disorder that is
highly comorbid with major depression, also have deficits in AlloP le-
vels. Based on the ratio of AlloP to its precursor, 5α-dihy-
droprogesterone, it appears that men and women differ in which neu-
rosteroid synthetic enzymes are altered. Men exhibit defects consistent
with changes in 5AR and women demonstrate abnormalities in 3α-
hydroxysteroid dehydrogenase (Pineles et al., 2018; Rasmusson et al.,
2019).
4.3. Is postpartum depression a unique case?
Postpartum depression is an important subtype of depression that
has long been thought to involve changes in neurosteroids (Maguire,
2019; Maguire and Mody, 2008; Mody, 2019; Rincon-Cortes et al.,
2019). While milder, transient changes in mood are seen in many
women following pregnancy, PPD is a serious and persistent disorder
affecting up to 15% of women in the perinatal period, with timing of
onset extending from the third trimester of pregnancy to 6 months or so
following pregnancy (Pawluski et al., 2017; Stewart and Vigod, 2016).
During pregnancy, levels of steroid hormones, including neurosteroids
such as AlloP increase dramatically and the levels of these steroids
rapidly decline following birth of the baby (Fig. 3B). Rodent models
have provided strong support for the idea that the increased levels of
AlloP during pregnancy likely contribute to changes in the expression of
GABAAR subunits, particularly δ-subunits that may contribute most to
tonic inhibition (Mody, 2019). When the levels of AlloP plummet in the
postpartum period there appears to be a sudden imbalance in the ratio
of excitation to inhibition (E/I imbalance) (Fig. 3B, black line), and
these changes contribute to a hyperexcitable state (Isaacson and
Scanziani, 2011) that can be manifest as stress-like and depressive-like
behaviors. These behaviors can be corrected by agents that enhance
tonic inhibition including NAS (Maguire and Mody, 2008; Melon et al.,
2018). Interestingly, one model for postpartum psychiatric illness in-
volves knockout/knockdown of expression of δ-subunits. These female
mice show normal behavior in the absence of pregnancy, but exhibit
marked behavioral changes in the postpartum period, including stress-
like behaviors and poor infant care (with infanticide) (Maguire, 2019;
Maguire and Mody, 2008). Agents that increase tonic inhibition, in-
cluding NAS, can reverse the behavioral changes (Maguire, 2019).
The rapid and apparently sustained improvement of women with
PPD following intravenous infusions of brexanolone are consistent with
the hypothesis that directly replenishing AlloP is highly effective in
treating this disorder (Kanes et al., 2017; Meltzer-Brody et al., 2018).
However, there is also accumulating evidence that another NAS, SGE-
217, is effective in treating both women and men with major depres-
sion, particularly women outside the postpartum period, suggesting
that NAS may be effective across a broader range of psychiatric illnesses
(Gunduz-Bruce et al., 2019). It is also notable that in the clinical trials
done to date NAS exhibit beneficial effects on both depression and
anxiety symptoms.
4.4. How do changes in neurosteroid levels influence the effects of
exogenous NAS?
Studies in rodent chronic stress models and in humans suggest that
major depression may represent a set of disorders that involve states of
relative neurosteroid deficiency (Fig. 3A). Such conditions could con-
tribute to changes in input-output relationships and network activity
that have been described in hippocampus and other neural circuits in
depression-like conditions (Airan et al., 2007; Small et al., 2011;
Duman et al., 2019; Popoli et al., 2012). If this hypothesis is correct,
then it becomes important to consider the prevailing “neurosteroid
state” in understanding how exogenously administered NAS affect
neurons and circuits (Nin et al., 2008). Under such a model, defects in
5AR and neurosteroid synthesis would result in defects in the ability to
mount acute neurosteroid responses to stressors. States of neurosteroid
deficiency could in turn influence the effects that an exogenous steroid
exerts on local activity and network function. In the case of AlloP de-
ficiency, an exogenously applied steroid would encounter neurons with
low levels of intracellular endogenous steroids; in such a case, the in-
tracellular pool of steroids would be low and the intracellular com-
partment could serve as a “sink” for exogenous NAS (Jiang et al., 2016;
Li et al., 2007). Under conditions of active neurosteroid synthesis,
exogenous NAS would encounter neurons in which the intracellular
pool of steroids enhances access to membranous receptors, under the
assumption that the intracellular pool has capacity limits.
In prior studies, we have encountered conditions in hippocampal
neurons that provide tentative support for the intracellular pool hy-
pothesis (Jiang et al., 2016; Li et al., 2007). For example, young post-
natal neurons grown in culture have limited capacity to synthesize
neurosteroids. In these neurons, exogenously applied NAS readily ac-
cess intracellular compartments, resulting in a dampening of NAS ef-
fects on inhibitory responses evoked by activation of GABAARs at the
neuronal soma (Jiang et al., 2016). When CA1 hippocampal neurons
are more mature (e.g. postnatal day 30 in hippocampal slices), we
found that neurosteroids may contribute to forms of inhibition of spike
firing activated by stimulation proximal to pyramidal neuron cell
bodies (Izumi et al., 2007; Tokuda et al., 2010). Surprisingly, we found
that inhibitors of neurosteroid synthesis (5AR inhibitors) or function
(the NAS NAL, 17-PA) dampen this form of proximal inhibition (Izumi
et al., 2007; Tokuda et al., 2010), while treatments that increase neu-
rosteroid staining enhance this form of spike inhibition (Tokuda et al.,
2010). Using an antibody against 5α-reduced neurosteroids, we ob-
served that pyramidal neurons of juvenile rodents show variable
staining under baseline conditions and that the level of staining is in-
creased by neuronal stressors (Tokuda et al., 2011; Izumi et al., 2015;
Zorumski and Izumi, 2012).
5. Beyond GABA: other possible contributors to the effects of NAS
Increasing evidence indicates that changes in GABA activity in the
brain are likely to be important in the biology of major depression
(Duman et al., 2019; Luscher et al., 2011; Mohler, 2012; Luscher and
Mohler, 2019). Thus, the ability of NAS PAMs to broadly enhance both
tonic and phasic inhibition mediated by GABAARs forms a leading hy-
pothesis for mechanisms underlying psychotropic actions of these
agents. Robust PAM activity provides a way to enhance tonic and
phasic inhibition in key neural circuits that contribute to depression-
like behavior (Airan et al., 2007; Duman et al., 2019). NAS differ from
benzodiazepines, which require certain receptor subunit compositions
for effective modulation (Rudolph and Mohler, 2006), but it is less clear
how NAS differ from other allosteric GABA modulators that have broad
actions, including barbiturates and certain anesthetics. Hence, there is
interest in understanding whether alternative or additional NAS targets
may contribute to antidepressant and other psychotropic actions.
In addition to direct effects on GABAARs, NAS can promote the
expression and trafficking of GABAAR subunits likely via phosphor-
ylation of specific subunits by protein kinase C and perhaps other ki-
nases (Abramian et al., 2014). Mechanisms underlying the ability of
NAS to promote kinase activation and receptor trafficking are not en-
tirely clear, but changes in GABAAR subunit expression can result in
prolonged increases in tonic inhibition in dentate gyrus. Interestingly,
not all NAS share this ability to enhance tonic inhibition via metabo-
tropic changes in subunit expression and trafficking; enhanced subunit
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expression is observed with AlloP and THDOC but not with the syn-
thetic NAS, ganaxolone (Modgil et al., 2017). Changes in GABAAR ex-
pression provide a mechanism by which NAS can have lasting effects on
brain function that persist beyond the period of drug exposure. An in-
triguing target that could contribute to NAS-mediated changes in sub-
unit phosphorylation and expression are membrane progesterone re-
ceptors, a class of G-protein coupled receptors that are expressed in
brain and activated by AlloP (Thomas and Pang, 2012).
AlloP and other NAS PAMs also alter the function of ion channels
other than GABAARs. In particular, certain of these agents inhibit low
voltage activated (LVA) calcium channels (T-type channels). AlloP is a
partial inhibitor of T-channels and acts on T-channels at concentrations
that overlap with those needed for effects on GABAARs, with an EC50 of
0.9 μM for T-channels expressed in rodent dorsal root ganglion neurons.
Effects on T-channels, like effects on GABAARs, are enantioselective
with the unnatural enantiomer being an order of magnitude less potent
than AlloP (Pathirathna et al., 2005). Importantly, T-channels con-
tribute significantly to burst firing in many regions of the brain and
increases in burst firing in lateral habenula appear to contribute to
depressive-like behaviors in rodent models; inhibiting these channels
has antidepressant-like effects (Yang et al., 2018). AlloP and another
NAS that has prominent effects on T-channels but no effects on GA-
BAARs (e.g. (3β,5β,17β)-3-hydroxy-androstane-17-carbonitrile
(3β5βACN), also called 3β-OH or B260 in other publications, Fig. 2)
(Todorovic et al., 2004) inhibit burst firing in pyramidal neurons in the
subiculum at concentrations that are likely relevant to clinical use
(Joksimovic et al., 2019). Thus, effects on T-channels and burst firing
could be important for some clinical effects of NAS.
Earlier we described intracellular accumulation of exogenously ap-
plied NAS including prominent interactions with Golgi. It is thus pos-
sible that intracellular targets could contribute to therapeutic effects
(Fig. 3C and D). Importantly, AlloP-type NAS do not have prominent
actions on classical nuclear steroid hormone receptors although it is
possible that metabolism to other steroids (e.g., 5α-dihy-
droprogesterone) could result in progesterone-like actions (Rupprecht
et al., 1993, 1999). The most certain intracellular NAS targets identified
to date, based on photoaffinity labeling, are VDAC-1 (Darbandi-
Tonkabon et al., 2003) and β-tubulin (Chen et al., 2012a,b); specific
protein targets in Golgi remain unknown. VDAC is an important mi-
tochondrial protein that helps to regulate the mitochondrial perme-
ability transition pore (mPTP) that is important in regulating movement
of molecules across the external mitochondrial membrane and also
participating in intrinsic cell death pathways. There is evidence that
AlloP and perhaps other NAS can inhibit mPTP as a possible mechanism
contributing to neuroprotection (Sayeed et al., 2009), although AlloP
does not alter voltage-dependent gating of VDAC-1 (Cheng et al., 2019).
A NAS photoaffinity label interacts with a specific amino acid in VDAC,
glutamate-73 (Darbandi-Tonkabon et al., 2003), but it is presently
unknown whether this interaction contributes to changes in mPTP or
other effects on cellular function. Glu-73 along with threonine-83 and
three other sites are also labeled by cholesterol photoaffinity labels,
suggesting a more general regulatory mechanism for steroids on VDAC
(Budelier et al., 2017; Cheng et al., 2019); other studies indicate that
there is overlap in sites for NAS and cholesterol in other proteins
(Budelier et al., 2019).
Certain psychiatric illnesses including depression are thought to
involve altered mitochondrial function and energy metabolism (Manji
et al., 2012). NAS can promote cellular energy production via effects on
glycolytic and respiration-mediated energy metabolism, with AlloP
having its most prominent effects on respiration (Grimm et al., 2014).
Perhaps related to cellular energy metabolism, AlloP has been reported
to promote autophagy as a mechanism to dampen cellular stress (Liao
et al., 2009; Kim et al., 2012). Autophagy involves cellular machinery
that degrades and recycles cellular components to maintain energy in
response to stressful conditions (Galluzzi et al., 2016) (Fig. 3C).
NAS also have anti-inflammatory effects that could contribute to
their therapeutic actions (Langmade et al., 2006; Noorbakhsh et al.,
2014; VanLandingham et al., 2006) (Fig. 3D). Recent evidence indicates
that effects on inflammation may occur via toll-like receptor-4 (Balan
et al., 2019; Murugan et al., 2019), a receptor that is important in
regulating the function of monocytes and microglia. Additionally, NAS
photolabel the microtubule protein, β-tubulin, at cysteine-354, the
same amino acid at which colchicine acts (Chen et al., 2012a,b). In-
terestingly, colchicine has anti-inflammatory actions but it is unknown
whether NAS interactions with β-tubulin contribute to anti-in-
flammatory effects. Other studies indicate that certain NAS can alter the
function of microtubules and that these effects contribute to anti-
depressant-like effects in rodent models (Bianchi and Baulieu, 2012).
AlloP and related NAS also increase the expression of certain nu-
clear receptors including pregnane xenobiotic receptors (PXR) and the
liver xenobiotic receptors (LXR) (Frye et al., 2012; Irwin et al., 2014),
and AlloP and other steroids are direct LXR agonists (Fan et al., 2013;
Lamba et al., 2004; Langmade et al., 2006). Effects on these receptors
could provide mechanisms by which NAS modulate synthesis of other
intracellular modulators, including steroids, and regulate endoplasmic
reticulum cellular stress mechanisms (Rong et al., 2013). These effects
may contribute to anti-inflammatory and neuroprotective actions
(Langmade et al., 2006).
Finally, there is evidence that several types of clinically-used anti-
depressants promote neurogenesis in the dentate gyrus of adult rodents
(Santarelli et al., 2003). These new neurons intercalate into the cir-
cuitry of the dentate gyrus and help to dampen production of corti-
costerone and other stress modulators (Snyder et al., 2011; Surget et al.,
2011); the new dentate neurons also help to correct stress-related be-
haviors and changes in hippocampal signaling in chronic stress models
(Airan et al., 2007). AlloP also enhances dentate neurogenesis Irwin
et al. (2012), 2014; Wang et al. (2010), an effect that could contribute
to antidepressant actions as well as neuro-restorative effects
(Charalampopoulos et al., 2008). Mechanisms contributing to NAS-in-
duced neurogenesis are not certain, although effects on GABAARs could
help the survival and function of these neurons, particularly during
phases of development where GABA functions as an excitatory mod-
ulator of neurons. In this light it is interesting that certain anti-
depressants, including fluoxetine, can increase AlloP production (Pibiri
et al., 2008).
6. Summary & future considerations
Psychiatry is entering an exciting era as evidenced by the advent of
the first novel pharmacological treatments for major depression to ar-
rive on the scene in more than 30 years. These novel treatments, in-
cluding NAS, offer hope for patients with severe, complex and re-
fractory psychiatric syndromes. In this review we have focused on
unique aspects of NAS highlighting both their role as endogenous stress
modulators and their prospects for new directions in therapeutics. NAS
clearly target major signaling systems in brain as exemplified by their
prominent actions on GABAARs. Yet, effects on other ion channels such
as T-type calcium channels and intracellular actions must continue to
be studied to determine their possible roles in psychopharmacology. It
is possible that novel synthetic NAS can be developed that exhibit more
selective actions than AlloP, and these agents could lead to alternative
forms of treatment. It is also possible that NAS with activities at mul-
tiple receptors, for example combined GABA PAM and NMDA NAM
activity, can be developed that might have even greater therapeutic
efficacy taking advantage of both the NAS and ketamine advances
(Mennerick et al., 2001; Roth et al., 2004).
Important considerations for NAS going forward include side ef-
fects, abuse potential and interactions with other medications and drugs
of abuse. In clinical studies to date, brexanolone and SGE-217 have
been well tolerated with sedation and dizziness being the most pro-
minent side effects (Kanes et al., 2017; Meltzer-Brody et al., 2018;
Gunduz-Bruce et al., 2019). These drugs have also been administered to
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patients taking traditional antidepressants but potential interactions
with other medications remain uncertain. The abuse potential of NAS
also remains uncertain, but needs to be examined given the GABAergic
nature of the PAMs.
We have focused this review on possible mechanisms contributing
to antidepressant effects of NAS PAMs. At this point, these agents are
being considered for use in other disorders, including insomnia, anxiety
disorders and essential tremor. Recent studies of psychiatric illnesses
highlight the complex and overlapping genetics among these syn-
dromes (Brainstorm Consortium, 2018; Smoller et al., 2019), and the
possibility that the different syndromes share a common underlying
psychopathology factor (Caspi and Moffitt, 2018) and share neuro-
circuitry dysfunction across diagnoses (Etkin, 2019). This symptomatic
complexity and genetic and circuitry overlap suggest that powerful new
treatments like NAS may not prove to be illness specific, but rather may
be effective across a range of psychiatric disorders and possibly extend
to primary neurological disorders such as epilepsy and neurodegen-
erative disorders.
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